The Role of Lapatinib in the Preoperative Therapy of Breast Cancer

被引:0
|
作者
Hirsh, Rebecca L. [1 ,2 ]
DeMichele, Angela [1 ,2 ,3 ]
机构
[1] Univ Penn, Dept Med, Perelman Sch Med, Div Hematol Oncol, Philadelphia, PA 19104 USA
[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[3] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA
关键词
Neoadjuvant; HER2; Lapatinib; Trastuzumab; Breast cancer; PATHOLOGICAL COMPLETE RESPONSE; PHASE-II TRIAL; NEOADJUVANT THERAPY; ADJUVANT CHEMOTHERAPY; STAGE-II; TRASTUZUMAB; PLUS; DOCETAXEL; PACLITAXEL;
D O I
10.1007/s11912-011-0206-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Preoperative or neoadjuvant chemotherapy is a well-established modality in the treatment of nonmetastatic breast cancer. Patients initially considered inoperable may be able to achieve operable status after preoperative chemotherapy and patients initially considered not to be candidates for breast conservation may convert to breast conservation status. Human epidermal growth factor receptor 2 (Her2)-positive tumors have been shown to have a more aggressive course including early local relapse and metastasis when compared to Her2-negative breast cancers, but the optimal use of Her2-targeted agents is constantly evolving as new agents become available. Preoperative studies allow us to quickly assess the activity of new agents and combinations for particular biological subsets of breast cancer.
引用
收藏
页码:44 / 47
页数:4
相关论文
共 50 条
  • [1] The Role of Lapatinib in the Preoperative Therapy of Breast Cancer
    Rebecca L. Hirsh
    Angela DeMichele
    Current Oncology Reports, 2012, 14 : 44 - 47
  • [2] An overview of HER-targeted therapy with lapatinib in breast cancer
    McArthur, Heather
    ADVANCES IN THERAPY, 2009, 26 (03) : 263 - 271
  • [3] Lapatinib for breast cancer: a review of the current literature
    MacFarlane, Robyn J.
    Gelmon, Karen A.
    EXPERT OPINION ON DRUG SAFETY, 2011, 10 (01) : 109 - 121
  • [4] Lapatinib in the treatment of HER-2 overexpressing breast cancer
    Vrdoljak, E.
    Boban, M.
    Ban, M.
    JOURNAL OF BUON, 2011, 16 (03): : 393 - 399
  • [5] Lapatinib in metastatic breast cancer
    Frenel, J-S
    Bourbouloux, E.
    Berton-Rigaud, D.
    Sadot-Lebouvier, S.
    Zanetti, A.
    Campone, M.
    WOMENS HEALTH, 2009, 5 (06) : 603 - 612
  • [6] Lapatinib and lapatinib plus trastuzumab therapy versus trastuzumab therapy for HER2 positive breast cancer patients: an updated systematic review and meta-analysis
    Yuan, Ye
    Liu, Xumei
    Cai, Yi
    Li, Wenyuan
    SYSTEMATIC REVIEWS, 2022, 11 (01)
  • [7] Lapatinib in breast cancer: clinical experiences and future perspectives
    Giampaglia, M.
    Chiuri, V. E.
    Tinelli, A.
    De Laurentiis, M.
    Silvestris, N.
    Lorusso, V.
    CANCER TREATMENT REVIEWS, 2010, 36 : S72 - S79
  • [8] Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib
    Kaklamani, Virginia G.
    Siziopikou, Kalliopi
    Scholtens, Denise
    Lacouture, Mario
    Gordon, Jennifer
    Uthe, Regina
    Meservey, Caitlin
    Hansen, Nora
    Khan, Seema A.
    Jeruss, Jacqueline S.
    Bethke, Kevin
    Cianfrocca, Mary
    Rosen, Steven
    Von Roenn, Jamie
    Wayne, Jeffrey
    Parimi, Vamsi
    Jovanovic, Borko
    Gradishar, William
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 132 (03) : 833 - 842
  • [9] Lapatinib for Advanced or Metastatic Breast Cancer
    Opdam, Frans L.
    Guchelaar, Henk-Jan
    Beijnen, Jos H.
    Schellens, Jan H. M.
    ONCOLOGIST, 2012, 17 (04) : 536 - 542
  • [10] Targeted Therapy for Early and Locally Advanced Breast Cancer
    Untch, Michael
    BREAST CARE, 2010, 5 (03) : 144 - 152